Project title: Repurposing mirabegron in a novel topical formulation as a therapeutic for peripheral vascular disease
Researcher: Cameron Evans, PhD
Supervisors: Prof Gemma Figtree, A/Prof Sarah Glastras and Dr. Owen Tang within the Cardiovascular Discovery Group,
Kolling Institute, Royal North Shore Hospital.

Cameron Evans’ research focuses on developing a topical gel containing mirabegron and other TGA approved medications to address Peripheral Arterial Disease (PAD). PAD, a condition affecting blood vessels away from the heart and brain, results in impaired blood flow and, alarmingly, necessitates a limb amputation every two hours globally. The project aims to tackle this critical need by improving blood vessel function and potentially reducing amputations. 

Preclinical evidence indicates that mirabegron may promote new blood vessel formation by combating oxidative stress and enhancing limb survival in ischemic conditions. The research plan involves formulating a topical gel for direct application to affected areas. 

The goal is to initiate human clinical trials by 2026, conducted in collaboration with cardiology and endocrinology specialists at the Royal North Shore Hospital’s high-risk foot clinic. The project seeks to thoroughly evaluate the drug’s effects through human skin, cellular assays and in vivo models, assessing both functional and molecular changes. 

If successful, this bench-to-bedside research could significantly improve the quality of life for over 320 million people worldwide suffering from PAD and diabetic foot ulcers. Furthermore, it holds the potential to reduce the substantial healthcare burden associated with this condition.